Acquired perforating dermatoses and cabozantinib: A novel cutaneous toxicity

JDDG: Journal der Deutschen Dermatologischen GesellschaftVolume 22, Issue 4 p. 594-596 CLINICAL LETTER Acquired perforating dermatoses and cabozantinib: A novel cutaneous toxicity Diego Soto-García, Corresponding Author Diego Soto-García [email protected] orcid.org/0000-0001-6559-3108 Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Spain Correspondence Diego Soto-García, MD, DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Department of Dermatology, Av. Montecelo 0, 36164 Casas Novas, Pontevedra, Spain. Email: [email protected]Search for more papers by this authorHae Jin Suh-Oh, Hae Jin Suh-Oh Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, SpainSearch for more papers by this authorCarlos Álvarez, Carlos Álvarez Department of Pathology, University Hospital of Pontevedra, Pontevedra, SpainSearch for more papers by this authorSandra Martínez-Fernández, Sandra Martínez-Fernández orcid.org/0000-0003-4534-7828 Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, SpainSearch for more papers by this authorFrancisco Ramón García-Arroyo, Francisco Ramón García-Arroyo Departmen of Oncology, University Hospital of Pontevedra, Pontevedra, SpainSearch for more papers by this authorCarmen Couselo-Rodríguez, Carmen Couselo-Rodríguez Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, SpainSearch for more papers by this authorÁngeles Flórez, Ángeles Flórez Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, SpainSearch for more papers by this author Diego Soto-García, Corresponding Author Diego Soto-García [email protected] orcid.org/0000-0001-6559-3108 Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Spain Correspondence Diego Soto-García, MD, DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Department of Dermatology, Av. Montecelo 0, 36164 Casas Novas, Pontevedra, Spain. Email: [email protected]Search for more papers by this authorHae Jin Suh-Oh, Hae Jin Suh-Oh Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, SpainSearch for more papers by this authorCarlos Álvarez, Carlos Álvarez Department of Pathology, University Hospital of Pontevedra, Pontevedra, SpainSearch for more papers by this authorSandra Martínez-Fernández, Sandra Martínez-Fernández orcid.org/0000-0003-4534-7828 Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, SpainSearch for more papers by this authorFrancisco Ramón García-Arroyo, Francisco Ramón García-Arroyo Departmen of Oncology, University Hospital of Pontevedra, Pontevedra, SpainSearch for more papers by this authorCarmen Couselo-Rodríguez, Carmen Couselo-Rodríguez Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, SpainSearch for more papers by this authorÁngeles Flórez, Ángeles Flórez Department of Dermatology, University Hospital of Pontevedra, Pontevedra, Spain DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, SpainSearch for more papers by this author First published: 01 March 2024 https://doi.org/10.1111/ddg.15350Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Jayaram A, Zafeiriou Z, de Bono JS. Cabozantinib-getting under the skin of cutaneous toxicity. JAMA Oncol. 2015; 1: 535-536. 10.1001/jamaoncol.2015.0702 PubMedWeb of Science®Google Scholar 2Massey PR, Okman JS, Wilkerson J, Cowen EW. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer. 2015; 23: 1827-1835. 10.1007/s00520-014-2520-9 PubMedWeb of Science®Google Scholar 3Maruyama A, Katoh N. Perforating folliculitis triggered by bevacizumab administration. J Dermatol. 2020; 47: e298-e299. 10.1111/1346-8138.15415 PubMedWeb of Science®Google Scholar 4Fernández-Guarino M, Aldanondo I, González-García C, et al. [Gefitinib-induced perforating dermatosis]. Actas Dermosifiliogr. 2006; 97: 208-211. 10.1016/S0001-7310(06)73383-X PubMedGoogle Scholar 5Tsutsui K, Namikawa K, Mori T, et al. Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. J Dermatol. 2021; 48: e114-e115. 10.1111/1346-8138.15718 PubMedWeb of Science®Google Scholar 6Chiang B, Kamiya K, Sashikawa M, et al. Rare case of acquired perforating dermatosis induced by cetuximab. J Dermatol. 2020; 47: e11-e12. 10.1111/1346-8138.15098 PubMedWeb of Science®Google Scholar 7Lederhandler M, Beasley JM, Brinster NK, Nagler AR. Unusual eruption in association with sorafenib: a case of acquired perforating dermatosis, reactive perforating collagenosis type. Dermatol Online J. 2018; 24:13030/qt8b40k5kg. 10.5070/D32412042445 Google Scholar 8Kimura A, Kosumi H, Natsuga K, et al. Acquired perforating dermatosis induced by necitumumab. J Eur Acad Dermatol Venereol. 2022; 36(10): e822-e823. 10.1111/jdv.18306 CASPubMedWeb of Science®Google Scholar 9Vega Díez D, Gómez Zubiaur A, Medina Montalvo S. Reactive perforating collagenosis: a rare side effect associated with sorafenib. Rev Esp Enferm Dig. 2020; 112: 960-961. 10.17235/reed.2020.7138/2020 PubMedWeb of Science®Google Scholar 10Lee YS, Vijayasingam S, Tan YO, Wong ST. Acquired perforating dermatosis associated with recurrent hepatocellular carcinoma. Int J Dermatol. 1996; 35: 743-745. 10.1111/j.1365-4362.1996.tb00656.x CASPubMedWeb of Science®Google Scholar 11Kiliç A, Gönül M, Cakmak SK, et al. Acquired reactive perforating collagenosis as a presenting sign of hepatocellular carcinoma. Eur J Dermatol. 2006; 16: 447. PubMedWeb of Science®Google Scholar 12Harbaoui S, Litaiem N. Acquired perforating dermatosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 13, 2023. Google Scholar Volume22, Issue4April 2024Pages 594-596 ReferencesRelatedInformation